Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients
Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The study has three parts. Part 1 is a dose escalation to investigate the safety and
tolerability of ASP9521. Part 2 will evaluate the safety and tolerability and initial
anti-tumor activity of ASP9521. Part 3 of the study will be a Food Effect study.